StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$8.04+0.07 (+0.88%)

Close on Nov 18, 2026Market cap $228.52MP/E –Yield –

Arcturus Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Arcturus Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $29.37M, down 76.0% year over year. For fiscal 2025 it was $82.03M, down 46.1% from the year before. The highest annual figure on record is $206.00M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$82.03M-46.1%
FY2024Dec 31, 2024$152.31M-8.7%
FY2023Dec 31, 2023$166.80M-19.0%
FY2022Dec 31, 2022$206.00M+1566.8%
FY2021Dec 31, 2021$12.36M+29.6%
FY2020Dec 31, 2020$9.54M-54.1%
FY2019Dec 31, 2019$20.79M+32.0%
FY2018Dec 31, 2018$15.75M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.96M-89.5%
Q1 FY2026Mar 31, 2026$2.06M-93.0%
Q4 FY2025Dec 31, 2025$7.20M-68.4%
Q3 FY2025Sep 30, 2025$17.15M-58.8%
Q2 FY2025Jun 30, 2025$28.30M-43.2%
Q1 FY2025Mar 31, 2025$29.38M-22.7%
Q4 FY2024Dec 31, 2024$22.77M-26.2%
Q3 FY2024Sep 30, 2024$41.67M-7.7%
Q2 FY2024Jun 30, 2024$49.86M+374.0%
Q1 FY2024Mar 31, 2024$38.01M-52.7%
Q4 FY2023Dec 31, 2023$30.86M-80.8%
Q3 FY2023Sep 30, 2023$45.14M+237.6%
Q2 FY2023Jun 30, 2023$10.52M-61.2%
Q1 FY2023Mar 31, 2023$80.29M+1431.0%
Q4 FY2022Dec 31, 2022$160.29M+2666.5%
Q3 FY2022Sep 30, 2022$13.37M+448.6%
Q2 FY2022Jun 30, 2022$27.09M+1254.0%
Q1 FY2022Mar 31, 2022$5.24M+146.5%
Q4 FY2021Dec 31, 2021$5.79M+158.9%
Q3 FY2021Sep 30, 2021$2.44M+4.5%
Q2 FY2021Jun 30, 2021$2.00M-13.8%
Q1 FY2021Mar 31, 2021$2.13M-19.6%
Q4 FY2020Dec 31, 2020$2.24M-24.6%
Q3 FY2020Sep 30, 2020$2.33M-29.7%
Q2 FY2020Jun 30, 2020$2.32M-77.1%
Q1 FY2020Mar 31, 2020$2.65M-39.2%
Q4 FY2019Dec 31, 2019$2.97M-60.8%
Q3 FY2019Sep 30, 2019$3.32M-3.1%
Q2 FY2019Jun 30, 2019$10.15M+325.5%
Q1 FY2019Mar 31, 2019$4.35M–
Q4 FY2018Dec 31, 2018$7.58M–
Q3 FY2018Sep 30, 2018$3.42M–
Q2 FY2018Jun 30, 2018$2.39M–

More Arcturus Therapeutics figures

See a number that looks wrong?